Grant Details

General Overview

Grant Information

Grant name: Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

Funding organization: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Total funding amount: Up to $500,000 for R61 phase; R33 phase budget is not limited but must reflect actual needs.

Duration: Maximum of 5 years (2 years for R61 phase, 3 years for R33 phase)

Primary objective: To support exploratory and developmental clinical research on neurobiological mechanisms of substance use disorders.

Funding source: Federal government (NIH)

Funding type: Grant

Significance: Addresses critical public health issues related to substance use disorders.

Grant frequency: Recurring (multiple application deadlines)

Organizational Aspects

Eligible Organization Types

Higher Education Institutions

Public/State Controlled Institutions of Higher Education

Private Institutions of Higher Education

Nonprofits (with and without 501(c)(3) status)

For-Profit Organizations

Small Businesses

Local, State, County, City or Township Governments

Indian/Native American Tribal Governments (both federally recognized and others)

Federal Government Agencies

U.S. Territories or Possessions

Other: Independent School Districts, Public Housing Authorities, Faith-based Organizations, Regional Organizations, Foreign Institutions

Specific Qualifications

All PD(s)/PI(s) must have an eRA Commons account.

Applicant organizations must complete registrations with SAM, eRA Commons, and Grants.gov.

Scope and Focus

Research Focus Areas

Understanding neurobiological mechanisms underlying substance use disorders.

Exploratory studies on neural circuitry and behavior related to substance use.

Innovative methodologies to enhance health-related research.

Expected Outcomes

Development of novel techniques, methodologies, and applications impacting SUD research.

Quantitative milestones for assessing progress.

Technical Details

Technical Expertise Requirements

Applicants are encouraged to include preliminary data if available.

Proposed milestones should be quantitative and clinically meaningful.

Financial Structure

Budget Information

R61 phase budget: Combined direct costs may not exceed $500,000 for up to 2 years.

R33 phase budget: Not limited but must reflect actual project needs.

Timeline and Implementation

Key Dates

Open Date: May 21, 2023

Application Due Dates: Multiple deadlines from June 21, 2023, to March 13, 2026.

Expiration Date: May 08, 2026

Compliance and Requirements

Regulatory Compliance

Compliance with NIH Grants Policy Statement is required.

Data Management and Sharing Plan must be included.

Application Process

Submission Requirements

Applications must be submitted electronically via Grants.gov.

Follow the SF424 (R&R) Application Guide for detailed instructions.

Grant Details

substance use disorder clinical research neuroscience healthcare mental health public health innovation biomedical research
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
PAR-23-157
NIH Grants
EDU NGO PUBLIC ENTERPRISE SME OTHER
US
HEALTHCARE OTHER
DEVELOPMENT OTHER
OTHER
SDG3
FUNDING RESEARCH_DEVELOPMENT
None
500000.00
None
500000.00
USD
None
March 13, 2026, 10 p.m.
Not specified